Plné znění - 2/2008 Sb. m. s.

Xxxxxxxxxxxx xxxxxxxxxxxx xxxx sděluje, že xxx 16. listopadu 2007 bylo xxxxxxxxxx xxxxxxxxx UNESCO, xxxxxxxxxxx Xxxxxxxxxxx xxxxxx xxxxx xxxxxxx xx xxxxxx¹⁾, xxxxxxxx xxxxxxxxx xxxxxx xxxxx Přílohy I - Xxxxxxx xxxxxxxxxx látek x xxxxx dopingu.

Xxxxxxx X xxxxxxxxx x platnost x xxxxxxx x článkem 34 xxxx. 3 Xxxxxx xxx 1. xxxxx 2008 a xxxxx xxxx xxxxxxxxx x xxxxxxxx x xxx Xxxxxx xxxxxxxxx. Xxxx xxxxxx Xxxxxxx X x xxxxxxxx přestává xxxxxx Xxxxxxx X Xxxxxxxxxxx xxxxxx proti xxxxxxx ve sportu xx xxxxx xxx xxx 2007, xxxxxxxxx xxx x. 59/2007 Xx. m. s.

Xxxxxxxx xxxxx Xxxxxxx X x její xxxxxxx xx xxxxxxx xxxxxx xx vyhlašují xxxxxxxx.

X1. ANABOLICKÉ XXXXX

Xxxxxxxxxx xxxxx xxxx xxxxxxxx.

1. XXXXXXXXXX XXXXXXXXXX STEROIDY (AAS):

x. Exogenní * XXX, xxxxxxxxxx:

1-xxxxxxxxxxxxx (5α-xxxxxxx-1-xx-3β,17β-xxxx); 1-androstendion (5α-androst-1-en-3,17-dion); xxxxxxxxx (19-norandrostendiol); xxxxxxxxxx; xxxxxxxx; boldion (xxxxxxxx-1,4-xxxx-3,17-xxxx); xxxxxxx (17α-xxxxxxx-17β-xxxxxxxxxxxxxx-4-xxx[2,3-x]xxxxxxxx); xxxxxxxxxxxxxxxxxxxxxxxxxxxxx (4-xxxxxx-17β-xxxxxxx-17α-xxxxxxxxxxxxx-1,4-xxxx-3-xx); xxxxxxxxxxxxxxxxxxxxxxx (17α-xxxxx-5α-xxxxxxx-2-xx-17β-xx); xxxxxxxxxxx; xxxxxxxxxxxxx (19-nor-17α-pregn-4-en-17-ol); xxxxxxxxxxxxxx; xxxxxxxxxx; furazabol (17β-xxxxxxx-17α-xxxxx-5α-xxxxxxxxxx[2,3-x]-xxxxxxx); xxxxxxxxx; 4-hydroxytestosteron (4,17β-xxxxxxxxxxxxxxxx-4-xx-3-xx); kalusteron; xxxxxxxxx; xxxxxxxxxx; xxxxxxxxxx; xxxxxxxxxxx (17β-xxxxxxx-17α-xxxxxxxxxxxxx-1,4-xxxx-3-xx); xxxxxxxxx; methandriol; xxxxxxxxxx (2α, 17α-xxxxxxx-5α-xxxxxxxxx-3-xx-17β-xx); xxxxxxxxxxxxxx (17β-hydroxy-17α-metylestra-4,9-dien-3-on); xxxxxx-1-xxxxxxxxxxx (17β-xxxxxxx-17α-xxxxx-5α-xxxxxxx-1-xx-3-xx); xxxxxxxxxxxxxxxxxxxx (17β-xxxxxxx-17α-xxxxxxxxx-4-xx-3-xx); xxxxxxxxxxxxxxx (17β-xxxxxxx-17α-xxxxxxxxxx-4,9,11-xxxxx-3-xx); methyltestosteron; xxxxxxxxx; xxxxxxxxx; 19-xxxxxxxxxxxxxxxx (xxxx-4-xx-3,17-xxxx); norboleton; norethandrolon; xxxxxxxxxxxx; oxabolon; xxxxxxxxxx; xxxxxxxxxxx; oxymetolon; xxxxxxxxxxx ([3,2-x]xxxxxxx-5α-xxxxxxxxxxxxxx-17β-xxxxxxxxxxxxxxxxx); quinbolon; xxxxxxxxxx; xxxxxxxxx; 1-testosteron (17β-hydroxy-5α-androst-1-en-3-on); xxxxxxxxxxxxxxxxxxx (18α-xxxx-xxxxxx-4,9,11-xxxxx-17β-xx-3-xx); trenbolon x xxxxx xxxxx x podobnou xxxxxxxxx xxxxxxxxxx xxxx xxxxxxxxx xxxxxxxxxxxx účinky.

b. Xxxxxxxxx ** XXX:

Xxxxxxxxxxxxx (androst-5-en-3β,17β-diol), xxxxxxxxxxxxx (xxxxxxx-4-xx-3,17-xxxx), xxxxxxxxxxxxxxxxxx, xxxxxxxxx (xxxxxxxxxxxxxxxxxxxxx, DHEA), xxxxxxxxxxx x xxxxxxxxxxx metabolity x xxxxxxx:

5α-xxxxxxxxx-3α,17α-xxxx xxxxxxx-5-xx-3β,17α-xxxx

5α-xxxxxxxxx-3α,17β-xxxx 4-xxxxxxxxxxxxx (xxxxxxx-4-xx-3β,17β-xxxx)

5α-androstan-3β,17α-diol 5-androstendion (xxxxxxx-5-xx-3,17-xxxx)

5α-xxxxxxxxx-3β,17β-xxxx xxx-xxxxxxxxxxxxxxxxxx

xxxxxxx-4-xx-3α,17α-xxxx 3α-xxxxxxx-5αxxxxxxxxx-17-xx

xxxxxxx-4-xx-3α,17β-xxxx 3β-xxxxxxx-5αxxxxxxxxx-17-xx

xxxxxxx-5-xx-3β,17α-xxxx 19-xxxxxxxxxxxxxx

androst-5-en-3α,17α-diol 19-noretiocholanolon

xxxxxxx-5-xx-3α,17β-xxxx

X xxxxxxxxx, xxx xxxx xxxx xxxxxxxxxx xxxxxxxxxx xxxxxxxxxx xxxxxxx xxxxxxxxx, xxxx xx mít xx to, xx Xxxxxx obsahuje tuto Xxxxxxxxx látku x xxxx xxxxxx xxxxxxxxx Xxxxxxxxx xxxxxxxxxxx xxxxx, xxxx xx xxxxxxxxxxx Xxxxxxxx xxxxx xxxx xxxxxx xxxxxxxxxx xxxx xxxxxxxxxxx x/xxxx když xx jakýkoli xxxx xxxxxxxxx xxxxx xx Xxxxxx Sportovce významně xxxxxxxxx xx rozmezí xxxxxx, které se xxxxxxxx xxxxxxxxx x xxxx tak, xx xxxxxxxxxx xxxxxxxx endogenní xxxxxxxx. Nebude se xxx xx to, xx Xxxxxx xxxxxxxx Xxxxxxxxx xxxxx v xxxxxxx případě, xxxxx Xxxxxxxxx prokáže, xx xx xxxxxxxxxxx Xxxxxxxx xxxxx xxxx xxxxxx xxxxxxxxxx xxxx indikátorů x/xxxx příslušný xxxxx xx Xxxxxx Sportovce xxxxxxxx fyziologickým xxxx xxxxxxxxxxxx stavem.

Bude xx xxx xx xx, xx Xxxxxx Xxxxxxxxx xxxxxxxx Zakázanou xxxxx x xxxxxxxxx xxxxxxx Xxxxxxxxx xxxxxxxxxxx xxxxx xx xxxxx xxxxxxxxx x xxx xxxxxxxxx xxxxxxxxxxx, pokud xxx podle spolehlivé xxxxxxxxxx xxxxxx (xxxx. XXXX) xxxxxxxx, že xx Xxxxxxxx xxxxx xxxxxxxxxx původu. V xxxxxxx xxxxxxx xxxx xxxxx provádět další xxxxxxx.

Xxxx xx xxxxxxx výsledku xxxxxxx xxxxxxxx xxxxxxxxxxx xx xxxxxxx xxxxxx, které xx xxxxxxxx xxxxxxxxx x xxxx x xxxxx spolehlivá analytická xxxxxx (xxxx. XXXX) xxxxxxxxxxx xxxxxxxx původ Xxxxxxxx látky, xxx xxxxxxxx xxxxxx použití Xxxxxxxx látky, xxxx xxxx. xxxxxxxxx s xxxxxxxxxxx xxxxxxxxxxxx xxxxxxxxxxx xxxxxxx, xxxx když xxxxxxxxx xxxxxxxxx xxxxx X/X vyšší než xxxxx (4) ku xxxxx (1) x xxxxx xxxxxxxxxx analytická xxxxxx (např. XXXX) xxxxxxxxxxx exogenní xxxxx xxxxx, xxxxxxx příslušná Xxxxxxxxxxxxx xxxxxxxxxx další xxxxxxx xxxxxxxxxx xxxxxxxx xxxxxxxxxx xxxxx xxxx xxxxxxxxxx xxxxxxxxxx xxxxx.

Xx-xx xxxxxxxxxx xxxxxx xxxxx xxxxxxx, pak xxxxxxxx xxxx laboratoří xxxxxx xxxx neobvyklý x xx xxxx xxxxxxxxx. Xxxxx xxxxxxxxx xxxxxxx, xx xxxxxxx xxxxxxxxxx analytické metody (xxxx. XXXX) xxxxxxxx xxxxx Xxxxxxxx xxxxx, xxxx nutné provádět xxxxx xxxxxxx, x xxxx xx mít xx xx, xx Xxxxxx obsahuje Zakázanou xxxxx. Xxxxx nebyla xxxxxxx xxxxxxxxxx xxxxxxxxxx xxxxxx (xxxx. XXXX) x xxxxxx k xxxxxxxxx xxxxxxxxx 3 xxxxxxxxx xxxxx, xxxx xxxxxxx xxxxxxxxxxxxxx xxxxxx Xxxxxxxxx xxx, xx xxxx xxxxxxxxxx Antidopingovou xxxxxxxxxx v následujících 3 xxxxxxxx xxxxxxx xxxxxxxx xxx xxxxxxxxxxx xxxxxxxx. Xxxxxxxx, xxxxx xxxxxxxxxx tuto xxxxxxxxxxxxxx xxxxxx, bude hlášen xxxx xxxxxxxxx. Xxxxx xxxxxxxxxxxxxx xxxxxx Xxxxxxxxx, xxxxxxxx následnými xxxxx, xxxx fyziologicky normální, xxxx xx pak xxxxxxxxx za Xxxxxxxxx xxxxxxxxxxx xxxxx.

V xxxxxxxx vzácných xxxxxxxxxxxxxx xxxxxxxxx xxxx xxx x xxxx xxxxxx xxxxxxx xxxxxxxx xxxxxxxxxxx xxxxxx xx xxxxxx xxxxxx xxxxxxxxxxxxx (xx/xx). Xxxxx xxxxxxxxx xxxxxx xxxxx nahlásila x xxxxxxx spolehlivé xxxxxxxxxx xxxxxx (xxxx. XXXX) xxxxxxxxxxx xxxxxxxx xxxxx Xxxxxxxx látky, xxxx xxx xxxxxxxxx další xxxxxxx provedením xxxxxxxxxx xxxxx (následných xxxxx).

Xxxxx laboratoř xxxxxxxxx Xxxxxxxxx xxxxxxxxxxx nález 19-xxxxxxxxxxxxxxx, xxxx xx xx xxxxxxxxx xx xxxxxxx a xxxxxxxxxxx xxxxx exogenního xxxxxx Xxxxxxxx xxxxx. X xxxxxxx xxxxxxx není xxxxx provádět xxxxx xxxxxxx.

X xxxxxxx, xx Xxxxxxxxx xxxxxx xxxxxxxxxxxxx při xxxxxxx xxxxxxxxx, bude xx xxx xx to, xx Xxxxxx Xxxxxxxxx xxxxxxxx Zakázanou xxxxx.

2. Ostatní xxxxxxxxxx xxxxx, xxxxxxxxxx:

Klenbuterol, xxxxxxxxxx xxxxxxxxxx xxxxxxxxxxxxx xxxxxxxxx (SARM), tibolon, xxxxxxx, zilpaterol, xxx xx s xxxxxxxx xxxxx xx xx.

S2. XXXXXXX X XXXXXXXX XXXXX

Xxxxxxxxxxx látky x jejich xxxxxxxxxx xxxxxxx jsou xxxxxxxx:

1. Erytropoetin (XXX);

2. Xxxxxxx xxxxxx (xXX), xxxxxxxx podobné xxxxxxx xxxxxxx (xxxx. XXX-1), xxxxxxxxxx xxxxxxx xxxxxxx (XXX);

3. Xxxxxxxxxxxxx (xxxx. XX, xXX), xxxxxxxx jen x xxxx;

4. Xxxxxxxx;

5. Xxxxxxxxxxxxxx

x xxxxx xxxxx x podobnou xxxxxxxxx xxxxxxxxxx xxxx xxxxxxxxx xxxxxxxxxxxx účinky.

Pokud Xxxxxxxxx xxxxxx prokázat, xx koncentrace xxxx xxxxxxxxx fyziologickým či xxxxxxxxxxxx stavem, xxxx xx mít za xx, xx Xxxxxx xxxxxxxx Xxxxxxxxx látku (xxx je uvedeno xxxx) x případech, xxx xxxxxxxxxxx Zakázané xxxxx nebo xxxxxx xxxxxxxxxx xx indikátorů x/xxxx xxxxxxxxx poměry xx Xxxxxx Xxxxxxxxx xxxxxxx překročí xxxxxxx xxxxxxxx xxxxxxxx x xxxx xxx, xx xxxxxxxxxxxx normální xxxxxxxxx xxxxxxxx.

Pokud xxxxxxxxx xxxxxxxxx, xx užití xxxxxxxxxx xxxxxxxxxx metody, xx Zakázaná látka xx xxxxxxxxxx xxxxxx, xxxx xx mít xx to, xx Xxxxxx obsahuje Xxxxxxxxx xxxxx x xxxx xxxxxxx Xxxxxxxxx xxxxxxxxxxx xxxxx.

X3. XXXX-2 XXXXXXXX

Xxxxxxx xxxx-2 xxxxxxxx xxxxxx xxxxxx X- x X-xxxxxxx xxxx xxxxxxxx.

Xxxxxxxx xxxx xxxxxxxxxx, xxxxxxxxxx, xxxxxxxxxx x xxxxxxxxxx, xxx xxxxx xx xxx inhalaci xxxxx xxxxxxx xxxxxxxx xxxxxxxxxxxx xxxxxxx.

I xxxx xxxx udělena xxxxxxxx forma xxxxxxxxxxxx xxxxxxx, xxxx xxxxx xxxxxxxxxxx (volný xxxx xxxxxxxxxx) xxxxx než 1000 nanogramů v 1 xxxxxxxxx xxxx xxxxxxxxx xx Xxxxxxxxx xxxxxxxxxxx nález, pokud Xxxxxxxxx neprokáže, xx xxxxxxxxxx výsledek byl xxxxxxxx xxxxxxxxxxxxx užíváním xxxxxxxxxxx x xxxxxxxx.

X4. XXXXXXXXXXX X MODULÁTORY HORMONŮ

Xxxxxxxxxxx skupiny xxxx xxxxxxxx:

1. Inhibitory xxxxxxxx, xxxxxxxxxx:

2. Selektivní xxxxxxxxxx xxxxxxxxxxxxx xxxxxxxxx (SERM), xxxxxxxx:

3. Xxxxxxx antiestrogenní xxxxx xxxxxxxxxx:

4. Xxxxx xxxxxxxxxxxx xxxxxx xxxxxxxxxx xxxxxx inhibitorů xxxxxxxxxx, ale xx x xxxxxxxx xxxxx xx xx.

X5. XXXXXXXXX A XXXXXXX XXXXXXXXX XXXXX

Xxxxxxxxx látky xxxx xxxxxxxx. Xxxxxxxx:

Xxxxxxxxx*, xxxxxxxxxxxxxx, xxxxxxxxxx, xxxxxxxxxx xxxx-xxxxxxxxx (např. xxxxxxxxxx, xxxxxxxxxx), xxxxxxxxxxxxxxx (xxxx. xxxxxxx, xxxxxxx, xxxxxxxxxxxxxxxxx) a xxxxx xxxxx x xxxxxxxxx xxxxxxxxxxxx xxxxxx.

Xxxxxxxxx xxxxxxxx:

Xxxxxxxxxxxx, amilorid, xxxxxxxxx, xxxxxxxxx, xxxxxxxxxxxx, xxxxxxxxx, kanrenon, xxxxxxxx xxxxxxxxxx, metolazon, xxxxxxxxxxxxx, xxxxxxxx (např. xxxxxxxxxxxxxxxxxx, xxxxxxxxxxxxxxxxxx, chlorothiazid), triamteren x xxxxx xxxxx x podobnou xxxxxxxxx xxxxxxxxxx xxxx xxxxxxxxx xxxxxxxxxxxx účinky (kromě xxxxxxxxxxxx, xxxxx xxxx xxxxxxxx).

* Xxxxxxxxxxxx xxxxxxx xxxx xxxxxx, xxxxx xxx Sportovce xxxxxxxx xxxxxxxxx xx xxxxxxx x xxxxxxxx xxxx xxxxxxxxxxx hladinou xxxx Xxxxxxxx xxxxx (xxxxx).

X1. XXXXXXXXX XXXXXXX XXXXXXX

Zakázané xx xxxxxxxxxxx:

M2. XXXXXXXX X FYZIKÁLNÍ XXXXXXXXXX

X3. XXXXXX XXXXXX

Neterapeutické xxxxxxx xxxxx, xxxx, xxxxxxxx xxxxxxxx, nebo xxxxxxxxxx xxxxxxx xxxx, xxxxx xxxx xxxxxxxxx xxxxxx sportovní xxxxx, xx zakázané.

X6. XXXXXXXXXXX

Xxxxxxx xxxxxxxxxxx (včetně xxxx xxxxxx xxxxxxxxxx xxxxxxxxx (X- x L-) xxxxxxx) jsou xxxxxxxx, x výjimkou xxxxxxxx xxxxxxxxx v xxxxxxx xxxxxx místního xxxxx x xxxxxxxxxxx zahrnutých xx Xxxxxxxxxxxxxx programu xxx rok 2008.

Xxxxxxxxxxx zahrnují:

Adrafinil, xxxxxxxxx**, xxxxxxxxxx, amfetaminil, xxxxxxxxxx, xxxxxxxxx, xxxxxxxxxxx, xxxxxxxxxxxxxxx, bromantan, xxxxxxxxxx, xxxxxxxxxxxxxxxxx, efedrin****, xxxxxxxx, xxxxxxxxx, xxxxxxxxxxxxxx, xxxxxxxxxxx, xxxxxxxxxxx, xxxxxxxxxxxxx, xxxxxxxxx, xxxxxxxxxxx, xxxxxxxxxxx, xxxxxxxx, xxxxxxxxxxx, xxxxxxxxxxxxx, fenproporex, xxxxxxxxx, 4-fenylpiracetam (xxxxxxxx), xxxxxxxxxx, xxxxxxxxxx, xxxxxxxxxxxx, xxxxx***, xxxxxxxxxxx, kokain, xxxxxxxxxxx, xxxxxxxxxx, xxxxxxxxxxxxxxx, xxxxxxxxx, xxxxxxxxxxx, xxxxxxxxxxxx, xxxxxxxxxxxx (D-), metylefedrin****, xxxxxxxxxxxxxxxxxxxxxx, methylendioxymetamfetamin, xxxxxxxxxxxxx, xxxxxxxx, xxxxxxxxx, xxxxxxxxx, xxxxxxxxxxx, xxxxxxxxxxxxxx, xxxxxxxxx, xxxxxxxxx, oxilofrin, xxxxxxxxxxxxxxxxxxxx, xxxxxxx, xxxxxxxxxxx, p-methylamfetamin, xxxxxxxxx, xxxxxxxxxxxxxx, xxxxxxxxx, xxxxxxxxxx, strychnin, tuaminoheptan x xxxxx xxxxx x xxxxxxxx chemickou xxxxxxxxxx xxxx xxxxxxxxx xxxxxxxxxxxx xxxxxx.

Xxxxxxxxxxxx xxxxxxxxx xxxxxxxx xxxx příklady x xxxxx xxxxxx xxxx xxxxxxxxxx xx specifickou xxxxx xxxxx, xxxxx Xxxxxxxxx xxxxxxx, že xxxx xxxxxxxxx dostupnost x xxxxxxx xxxxxxxxx xxxxxxxxxxx xxxxxxxx neúmyslné xxxxxxxx xxxxxxxxxxxxxxx pravidel, xxxx xx x xxx xxxxx xxxxxxxxxxxxxxx, xx xxxx xxxxxxx xxxxxxxx xxxx dopingová xxxxx.

X7. XXXXXXXXX

Xxxxxxxxxxx xxxxxxxxx xxxx xxxxxxxx:

Xxxxxxxxxxx, xxxxxxxxxxxxx, xxxxxxxxx(xxxxxx), fentanyl x xxxx deriváty, xxxxxxxxxxx, metadon, xxxxxx, xxxxxxxx, xxxxxxxxx, xxxxxxxxxx, xxxxxxx.

X8. XXXXXXXXXXX

Xxxxxxxxxxx (xxxx. xxxxx, xxxxxxxxx) xxxx xxxxxxxx.

X9. XXXXXXXXXXXXXXXXXXXX

Xxxxxxx xxxxxxxxxxxxxxxxxxxx xxxxxxxx orálně, rektálně, xxxxxxxxxx nebo xxxxxxxxxxxxx xxxxxxxx xxxx zakázané. Xxxxxx xxxxx xxxxxxxx xxxxxxxxxxxxx výjimku.

Jiné xxxxxxx xxxxxxxx aplikace (xxxxxxxxxxxx, xx xxxxx xxxxxx, xx xxxxx xxxxxx, epidurální, xx xxxx) a xxxxxxxxx xxxxxxxx xxxxxxxx xxxxxxxxx xxxxxxxxxxxxx xxxxxxx s xxxxxxxx xxxx xxxxxxxxx.

Xxxxxxx xxxxxxxxx xxxxxxxx xx potíže xxxxx (xxxxxx xxxxxxxxxxx/xxxxxxxxxx), ušní, xxxxx, xxxx, xxxxxx xxxxx xxxxxxx xxxxxx, xxxxxxxx xxx x xxxxx xxxxxx xxxxxxxx x xxxxxxxxxx žádnou xxxxx terapeutické xxxxxxx.

X1. XXXXXXX

Xxxxxxx (xxxxxx) xx xxxxxxxx pouze Xxx soutěži x xxxxxxxxxxxxx sportech. Xxxxxxx xx bude xxxxxxxx xxxxxxxx xxxxxxxx x/xxxx xxxxxxxx krve. Xxxxxxx xxxxxxx xxx porušení xxxxxxxxxxx xxxxxxxx (hematologická xxxxxxx) je pro xxxxxx federaci xxxxxxx x závorkách.

∙ Xxxxxxxxxxxx xxxxx (XXX) (0.10 g/l)

∙ Xxxxxx (WKF) (0.10 x/x)

∙ Xxxxxxx xxxxxx a parašutismus (XXX) (0.20 x/x)

∙ Xxxxxxxxxxx (XXXX, XXX) (0.10 x/x)

∙ Xxxxxxx pětiboj (XXXX) jen pro xxxxxxxxxx xx střelbou (0.10 x/x)

∙ Motocyklový xxxxx (XXX) (0.10 x/x)

∙ Xxxxx xxxxxxxxxx (XXX) (0.30 g/l)

∙ Kuželky (IPC) (0.10 g/l)

X2. XXXX-XXXXXXXXX

Xxxxx xxxx xxxxx xxxxxx, xxxx-xxxxxxxxx xxxx xxxxxxxx xxxxx Xxx soutěži x xxxxxxxxxxxxx sportech.

∙ Automobilový xxxxx (XXX)

∙ Xxxxxxxx (XXXX)

∙ Xxxx (XXXX)

∙ Bridž (XXX)

∙ Xxxxxxx (XXX)

∙ Gymnastika (XXX)

∙ Xxxxxxxx (XXXX) - "match xxxx" - xxx xxxxxxxxxxx

∙ Xxxxxxx (XXX)

∙ Letecké xxxxxx x xxxxxxxxxxxx (XXX)

∙ Xxxxxxxxxxx (XXXX, IPC) (xxxxxxxx xxxx Mimo xxxxxx)

∙ Lyžování (XXX) - xxxxx xx xxxxxx a akrobatické xxxxxxxx-xxxxx a U-rampa, x xxxxxxxxx X-xxxxx x "big air"

∙ Xxxxxxx xxxxxxx (XXXX) - xxx xxxxxxxxxx xx xxxxxxxx

∙ Xxxxxxxxxxx sport (XXX)

∙ Petanque x obdobné xxxxxx (XXXX, XXX "xxxxx")

∙ Xxxxxxx (XXXX, XXX) (zakázané xxxx Xxxx soutěž)

∙ Xxxxx xxxxxxxxxx (UIM)

∙ Xxxxx (FILA)

Xxxx-xxxxxxxxx xxxxxxxx následující xxxxx:

Xxxxxxxxxx, xxxxxxxxxx, xxxxxxxx, xxxxxxxxx, xxxxxxxxxx, xxxxxxx, celiprolol, esmolol, xxxxxxxxx, karvedilol, xxxxxxxxx, xxxxxxxxxxx, metipranolol, metoprolol, xxxxxxx, oxprenolol, pindolol, xxxxxxxxxxx, xxxxxxx, timolol, xxx xx x xxxxxxxx xxxxx xx xx

"Xxxxxxxxxx látky"* xxxx vyjmenovány níže:

∙ Všichni Xxxx-2 xxxxxxxx x xxxxxxxx, xxxxx xxxxxxxxxxx (xxxxxxx xxxx xxxxxxxxxxx) xxx xxxxxxxx xxxxxx než 1000 xx/xx xxxx x clenbuterolu (xxxxxxx xx skupině X 1.2 Ostatní anabolické xxxxx);

∙ Xxxxxxxxxx xxxx-xxxxxxxxx, xxxxxxxxxx;

∙ Xxxxx, xxxxxxxxxxx, xxxxxxxxxx, xxxxxxx, xxxxxxxx, xxxxxxxxxxx, xxxxxxxxxxxxx, haptaminol, isomethepten, xxxxxxxxxxxxxxx, xxxxxxxxxxxx, p-metylamfetamin, xxxxxxxxxxxx, niketamid, xxxxxxxxxxx, xxxxxxxxx, xxxxxxxxx, xxxxxxxxx, xxxxxxxxxxxxxx, xxxxxxxxx, sibutramin, xxxxxxxxxxxxx x všechna xxxxxxx xxxxxxxxxxx neuvedená xxxxxxxx x xxxxxx X6, pro xxxxx Xxxxxxxxx xxxxxxx, xx xxxxxxx podmínky xxxxxxx x xxxxxx S6;

∙ Kanabinoidy;

∙ Xxxxxxx Xxxxxxxxxxxxxxxxxxxx;

∙ Xxxxxxx;

∙ Všechny Xxxx-xxxxxxxxx.

*"X Xxxxxxx xxxxx xxx xxxxxxxxxxx xxxxxxxxxx látky, které xxxxxxxx xxxxxxxx xxxxxxxxx xxxxxxxx antidopingových pravidel, xxxxxxx jsou všeobecně xxxxxxxx x běžných xxxxxxxxx xxxxxxxxxxx, xxxx x nichž xx xxxxx xxxxxxxxxxxxxxx, že xxxxx úspěšně zneužity xxxx dopingová činidla." Xxxxxxxx xxxxxxxxxxxxxxx pravidla xxxxxxxxxx xxxxxxxx látky xxxx xxxxxxxx xxxxxxx xxxxxx xx xxxxxxxxxxx, xx "...Xxxxxxxxx xxxx xxxxx xxxxxxxx, xx Xxxxxxx xxxxxxxxxx xxxxx xxxxxx zamýšleno ke xxxxxxx xxxxxxxxxxx výkonu...".

Xxxxxx xxxxxxx č. 2/2008 Xx. x. x. xxxxx účinnosti xxxx 31.1.2008.

Xxxxxx xxxxxxx x. 2/2008 Xx. x. x. byl xxxxxx xxxxxxx xxxxxxxxx č. 8/2009 Sb. m. s. x xxxxxxxxx od 7.2.2009.

Xxxxx xxxxxxxxxxxx právních norem xxxxxx xxxxxxxx xxxxxxxx x xxxxxxxx xxxx xxxxxxxxxxxxx, pokud xx xxxx xxxxxx derogační xxxxx xxxxx xxxxxxxxx xxxxxxxx xxxxxxxx.